Insmed Inc (INSM): Next-Year EPS Estimate 151.54%

As of 2026-09-18, Insmed Inc (INSM) has a next-year EPS growth estimate of 151.54%. Featured in our EPS revision report on 2026-08-07.

Latest revision: 157.16% → 151.54%
Revised on 2026-09-15 · estimate has held for 4 consecutive trading sessions

On 2026-09-15, analyst consensus for INSM's next-year EPS growth shifted from 157.16% to 151.54% — a negative change of 5.62 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at 75.03%.

What's Driving This

The primary structural driver is the 2026-09-01 upgrade to next-year EPS growth estimates, now at 157.16%, reflecting rising analyst confidence. This upgrade is plausibly connected to Insmed’s Q2 2026 results, where BRINSUPRI surged 49% sequentially, prompting the company to raise its revenue guidance and expand peak sales outlook. The positive earnings headlines and guidance increase support the upward EPS revision. Momentum has continued as the stock keeps rising beyond the initial revision date.

Generated 2026-09-09 from news as of 2026-09-09

Current Snapshot

Sector
Healthcare
Industry
Biotechnology
EPS growth next year
151.54%
EPS growth this year
75.03%
EPS next quarter (est)
-$0.39
Last price
$120.00

EPS Revision History

160.1%151.5%08-1908-2609-0309-1009-18
Next-year EPS growth estimate · latest 30 days · 28 observations
235.2%226.6%08-1908-2609-0309-1009-18
Combined EPS growth (this year + next year) · latest 30 days · 28 observations
DateEPS Next YEPS This YNext Q (est)Price
2026-09-18151.54%75.03%-$0.39$120.00
2026-09-17151.54%75.03%-$0.39$123.98
2026-09-16151.54%75.03%-$0.39$122.58
2026-09-15151.54%75.03%-$0.39$119.92
2026-09-14157.16%75.09%-$0.39$125.30
2026-09-13157.16%75.09%-$0.39$129.41
2026-09-11157.16%75.09%-$0.39$129.41
2026-09-10157.16%75.09%-$0.39$127.28
2026-09-09157.16%75.09%-$0.39$128.80
2026-09-08160.10%75.09%-$0.39$124.89
2026-09-07160.10%75.09%-$0.39$126.29
2026-09-06160.10%75.09%-$0.39$126.29
2026-09-04160.10%75.09%-$0.39$126.29
2026-09-03160.10%75.09%-$0.39$126.68
2026-09-02160.10%75.09%-$0.39$126.63
2026-09-01160.10%75.09%-$0.39$121.51
2026-08-31160.09%75.09%-$0.39$121.82
2026-08-30160.09%75.09%-$0.39$118.54
2026-08-29160.09%75.09%-$0.39$118.54
2026-08-28160.09%75.09%-$0.39$118.54
2026-08-27160.09%75.09%-$0.39$121.39
2026-08-26160.09%75.09%-$0.39$124.39
2026-08-25160.09%75.09%-$0.39$123.89
2026-08-24156.28%75.09%-$0.39$123.98
2026-08-23156.28%75.09%-$0.39$125.77
2026-08-21156.28%75.09%-$0.39$125.77
2026-08-20156.28%75.09%-$0.39$125.08
2026-08-19156.28%75.09%-$0.39$130.66
2026-08-18156.28%75.09%-$0.39$128.46
2026-08-17156.28%75.09%-$0.39$128.32

Reports Featuring INSM

Recent News

Screen Performance

Aggregate stats across all 2047 tickers our top-EPS-revision screen has flagged over the past 170 days.

Median return since detection
+0.3%
% of tickers in the green
51%
Median return on winners
+22.2%
Large revisions captured
1736

Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.

Also Tracked by Our Screen

Frequently Asked Questions

What is Insmed Inc's next-year EPS growth estimate?

As of 2026-09-18, Insmed Inc (INSM) has a next-year EPS growth estimate of 151.54%, based on analyst consensus.

When was the latest EPS estimate revision for INSM?

The most recent revision occurred on 2026-09-15, when analysts adjusted the next-year EPS growth estimate from 157.16% to 151.54%.

What sector and industry does Insmed Inc belong to?

Insmed Inc operates in the Healthcare sector, specifically the Biotechnology industry.

How often is this EPS estimate data updated?

EPS revision data is refreshed daily from analyst consensus estimates. INSM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.

EPS revision data sourced from analyst consensus estimates, refreshed daily. Insmed Inc (INSM) appears here because it was detected by our daily top-EPS-revision-performer screen.